Company Information

  

Address: 200 - 3650 GILMORE WAY  
City: BURNABY 
State:  
Zip Code: V5G 48W 
Telephone: (604) 484-3300 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that we intend to commercialize on our own, and for larger market indications that we intend to partner with global pharmaceutical companies. We have expertise in human genetics, small molecule drug discovery, as well as preclinical and clinical development that we intend to leverage to develop innovative therapeutics, including novel selective ion channel inhibitors. Our pharmaceutical partners include Teva Pharmaceutical Industries, Ltd., or Teva (through its subsidiary, Ivax International GmbH), Genentech, a member of the Roche Group, and Merck & Co., Inc., or Merck (through its affiliate, Essex Chemie AG).  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-1.67NAN/E
03/2017-1.68NAN/E
12/2016-1.48NAN/E
09/20160.77NA10.52
06/20163.19NA1.85
03/20161.51NA4.63
12/20151.10NA7.31
09/20150.74NA11.16

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.11Total Liab/Total Assets0.05
Net Inc/Total Assets-0.34Total Liab/Inv Cap0.06
Net Inc/Inv Cap-0.36Total Liab/Comm Equity0.02
Pretax Inc/Net Sales-12.75Interest Coverage RatioNA
Net Inc/Net Sales-12.75Curr Debt/EquityNA
Cash Flow/Net Sales-10.85LTD/EquityNA
SG&A/NetSales3.77Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover7.00Quick Ratio18.68
Inventory TurnoverNACurrent Ratio18.68
Inventory Day SalesNANet Rec/Curr Assets0.00
Net Sales/Work Cap0.03Inv/Curr AssetsNA
Net Sales/PP&E1.28  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 0.02 0.02 0.38 0.41
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 1.80 2.10 1.44 1.78
Operating Income -7.89 -7.99 -5.46 -7.33
Interest Exp NA NA NA NA
Pretax Income -7.38 -7.52 -6.00 -7.71
Other Income 0.51 0.47 -0.54 -0.38
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -7.38 -7.52 -6.00 -7.71

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 51.70 58.03 64.15 69.49
Receivables - Total 0.20 0.19 0.20 0.60
Inventories - Total NA NA NA NA
Total Current Assets 52.63 59.14 65.68 71.35
Net Property, Plant & Equipment 1.31 1.38 1.40 1.54
Total Assets 54.23 60.79 67.49 73.37
Liabilities        
Accounts Payable 3.77 3.59 3.52 3.98
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 3.77 3.59 3.52 3.98
Long-Term Debt NA NA NA NA
Total Liabilities 3.77 3.59 3.59 4.06
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 173.84 173.83 173.25 172.89
Retained Earnings -157.58 -150.20 -142.68 -136.70
Treasury Stock NA NA NA NA
Total Stockholders' Equity 50.45 57.20 63.90 69.31
Total Liabilities and Stockholders' Equity 54.23 60.79 67.49 73.37

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -6.80 -6.46 -4.67 -4.52
Net Cash Provided by Investing Activities 9.33 9.25 -32.23 -0.11
Net Cash Provided by Financing Activities 0.00 0.17 0.05 23.83

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201214.31-4.30--
12/201327.3612.03--
12/201428.3713.023.28
12/201515.58-15.751.10
12/20161.80-23.00-1.48
Growth Rates-40.42----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17439,94655.26




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.